Dispersyn Gerrit 4
4 · Phio Pharmaceuticals Corp. · Filed Mar 5, 2019
Insider Transaction Report
Form 4
Dispersyn Gerrit
Chief Development Officer
Transactions
- Award
Common Stock
2019-03-01+407,703→ 479,053 total
Footnotes (1)
- [F1]As reported on the Current Report on Form 8-K filed on February 15, 2019 and pursuant to the reporting person's appointment as CEO, the securities reported represent shares underlying a restricted stock unit, of which shares will vest in four equal annual installments. Additionally, the reporting person's right to receive the underlying shares at vesting is subject to stockholder approval of an increase in the authorized shares under the Company's equity compensation plan. In the event that such an increase is not approved, then no shares will be issued at the applicable vesting date.